Financial Performance Overview
PVP Ventures Limited reported a significant financial turnaround for FY 2025-26, achieving standalone net profit of ₹72.32 lakhs compared to a loss of ₹390.40 lakhs in the previous year. Standalone total income grew to ₹5,341.55 lakhs from ₹2,818.48 lakhs year-over-year. However, consolidated performance showed a net loss of ₹996.35 lakhs, though improved from ₹856.11 lakhs loss in FY25. The company's total assets expanded to ₹52,030.98 lakhs from ₹37,000.33 lakhs, while borrowings increased substantially to ₹20,598.74 lakhs from ₹3,201.03 lakhs.
Strategic Transformation and Acquisitions
The company is undergoing a fundamental transformation from diversified operations to an integrated healthcare platform focused on four pillars: Cancer Care, Renal Care, Senior Care, and Women's Health. This strategic shift is marked by three major acquisitions completed during FY26:
- Biohygea Global Private Limited (52% stake for ₹700.92 lakhs) for diagnostics expansion
- Optimus Oncology Private Limited (56.01% stake for ₹5,473.66 lakhs) for cancer care strengthening
- 7 Med India Private Limited (33.24% stake for ₹6,750.19 lakhs) for renal care expansion
Total investment in subsidiaries reached ₹17,990.25 lakhs, contributing to consolidated healthcare segment revenue of ₹5,678.80 lakhs.
Corporate Restructuring and Name Change
The Board has approved changing the company name from PVP Ventures Limited to Evervie Health Limited, subject to shareholder approval at the 35th Annual General Meeting scheduled for September 7, 2026. The company also received in-principle approval for merger with wholly-owned subsidiary Humain Healthtech Private Limited with appointed date of April 1, 2024.
Capital Structure and Financing
The company maintained its share capital at ₹26,040.37 lakhs but significantly increased debt through ₹150 crore NCD issuance to LICHFL in two series (Series A: ₹95 crore, Series B: ₹55 crore) at 18% interest plus 1% on redemption. Total borrowings reached ₹205.99 crore, secured by various assets including receivables, fixed assets, and specific properties, with personal guarantees from key promoters.
AGM Agenda and Corporate Governance
The 35th AGM agenda includes adoption of financial statements, appointment of new directors (including Ms. Saloni Khandelwal and Mr. Srivatsan Kalyanasundaram as Independent Directors), approval of material related party transactions aggregating ₹53.20 crores, and implementation of an Employee Stock Option Scheme for up to 2 crore shares (approximately 7.68% dilution). The company seeks approval for managerial remuneration of ₹5 crores for Chairman & MD Mr. Prasad V. Potluri for FY 2026-27.
Risk Factors and Contingencies
The company faces contingent liabilities of ₹179.73 crore primarily from income tax disputes, GST demands, and SEBI penalties. Financial risk management details show total financial assets of ₹26,013.17 lakhs, with loans comprising the largest portion at ₹13,973.47 lakhs. The company is addressing FEMA compliance issues and regularizing SEBI compliance matters.
Forward Outlook
The transformation into Evervie Health Limited positions the company to capitalize on demographic opportunities in the Indian healthcare sector, with growth prospects in specialty healthcare segments including oncology, diagnostics, and renal care. The strategic acquisitions provide a foundation for integrated healthcare service delivery across multiple therapeutic areas.